Should I buy or sell Xencor stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks .

What is Xencor's stock price target for 2024?

9 brokers have issued twelve-month target prices for Xencor's shares. Their XNCR share price targets range from $24.00 to $50.00. On average, they predict the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 88.9% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts .

How have XNCR shares performed in 2024?

Xencor's stock was trading at $21.23 at the start of the year. Since then, XNCR stock has decreased by 10.2% and is now trading at $19.06. View the best growth stocks for 2024 here .

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our XNCR earnings forecast .

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) issued its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of $0.36 by $0.67. The biopharmaceutical company had revenue of $44.70 million for the quarter, compared to analysts' expectations of $77.63 million. Xencor had a negative trailing twelve-month return on equity of 18.67% and a negative net margin of 74.90%. The company's revenue for the quarter was up 106.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.20) EPS.

What ETFs hold Xencor's stock?

ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Genomics Immunology and Healthcare ETF (IDNA) . ALPS Medical Breakthroughs ETF (SBIO) .

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com . Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I) , Bank of America (BAC) , Apollo Global Management (APO) , Cypress Semiconductor (CY) , NVIDIA (NVDA) , AbbVie (ABBV) , Exelixis (EXEL) , Intel (INTC) , AMC Entertainment (AMC) and Ciena (CIEN) .

Who are Xencor's major shareholders?

Xencor's stock is owned by many different institutional and retail investors. Top institutional investors include Diversified Trust Co (0.02%), Los Angeles Capital Management LLC (0.02%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Allen Yang , Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais and Kurt A Gustafson. View institutional ownership trends .

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XNCR

Xencor (XNCR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free XNCR Stock Alerts

$18.95

-0.12 (-0.63%)

(As of 04/18/2024 ET)

Compare

Today's Range: $18.72
▼
$19.16
50-Day Range: $18.65
▼
$26.52
52-Week Range: $16.49
▼
$28.96

Volume: 466,377 shs
Average Volume: 694,661 shs
Market Capitalization: $1.16 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Get Xencor alerts:

Xencor MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 88.9% Upside
$36.00 Price Target
Short Interest: Bearish
9.72% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.24
Upright™ Environmental Score
News Sentiment: -0.23
Based on 6 Articles This Week
Insider Trading: Selling Shares
$2.15 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.25) to ($3.07) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

234th out of 919 stocks

Pharmaceutical Preparations Industry

91st out of 415 stocks

4.4

Analyst's Opinion

Consensus Rating
Xencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Xencor has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.72% of the outstanding shares of Xencor have been sold short.
Short Interest Ratio / Days to Cover
Xencor has a short interest ratio ("days to cover") of 8.6.
Change versus previous month
Short interest in Xencor has recently increased by 6.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Xencor does not currently pay a dividend.
Dividend Growth
Xencor does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Xencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Xencor is -2.24.

1.0

News and Social Media Coverage

News Sentiment
Xencor has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Xencor this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,152,417.00 in company stock.
Percentage Held by Insiders
Only 4.97% of the stock of Xencor is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Xencor are expected to grow in the coming year, from ($3.25) to ($3.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xencor is -9.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xencor is -9.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xencor has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Xencor Stock (NASDAQ:XNCR)

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

XNCR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XNCR Stock News Headlines

April 17, 2024 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Price Target Lowered to $38.00 at BTIG Research

April 17, 2024 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Stock Price Down 4.5% Following Analyst Downgrade

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 16, 2024 | markets.businessinsider.com

Analyst Scoreboard: 6 Ratings For Xencor

April 11, 2024 | uk.investing.com

Xencor names Bart Cornelissen as new CFO

April 10, 2024 | markets.businessinsider.com

Xencor Appoints Bart Cornelissen As CFO

April 9, 2024 | marketwatch.com

Xencor Names Bart Cornelissen Chief Financial Officer

April 9, 2024 | finance.yahoo.com

Xencor Appoints Bart Cornelissen as Chief Financial Officer

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 9, 2024 | businesswire.com

Xencor Appoints Bart Cornelissen as Chief Financial Officer

April 9, 2024 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

March 16, 2024 | finance.yahoo.com

XNCR Apr 2024 30.000 call

March 9, 2024 | finance.yahoo.com

XNCR May 2024 22.500 put

March 7, 2024 | finance.yahoo.com

Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)

March 1, 2024 | markets.businessinsider.com

Xencor’s Strategic Focus and Pipeline Progress Affirm Buy Rating

March 1, 2024 | msn.com

Piper Sandler Downgrades Xencor (XNCR)

February 29, 2024 | morningstar.com

Xencor Inc XNCR

February 29, 2024 | finance.yahoo.com

Xencor Full Year 2023 Earnings: Misses Expectations

February 28, 2024 | seekingalpha.com

Xencor Q4 2023 Earnings Preview

February 28, 2024 | finance.yahoo.com

Xencor to Present at Upcoming Investor Conferences

February 28, 2024 | markets.businessinsider.com

Unveiling 4 Analyst Insights On Xencor

February 28, 2024 | msn.com

Xencor slips as Piper cuts citing patient death in cancer study

February 28, 2024 | markets.businessinsider.com

Xencor (XNCR) Gets a Buy from TD Cowen

February 28, 2024 | finance.yahoo.com

Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript

February 27, 2024 | sfgate.com

Xencor: Q4 Earnings Snapshot

February 27, 2024 | finance.yahoo.com

Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023

February 27, 2024 | businesswire.com

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

See More Headlines

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XNCR
CUSIP: N/A
CIK: 1326732
Web: www.xencor.com
Phone: (626) 305-5900
Fax: 626-305-0350
Employees: 280
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.00
High Stock Price Target: $50.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +89.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-126,090,000.00
Net Margins: -74.90%
Pretax Margin: -71.55%
Return on Equity: -18.67%
Return on Assets: -15.23%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 7.36
Quick Ratio: 7.36

Sales & Book Value

Annual Sales: $168.34 million
Price / Sales: 6.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.99 per share
Price / Book: 1.73

Miscellaneous

Outstanding Shares: 61,120,000
Free Float: 58,082,000
Market Cap: $1.16 billion
Optionable: Optionable
Beta: 0.76

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Bassil I. Dahiyat Ph.D. (Age 54)
Co-Founder, CEO, President & Director
Comp: $1.08M
Mr. John J. Kuch (Age 65)
Senior VP & CFO
Comp: $660.75k
Dr. John R. Desjarlais Ph.D. (Age 60)
Executive VP of Research & Chief Scientific Officer
Comp: $711.45k
Ms. Celia E. Eckert J.D. (Age 51)
Senior VP, General Counsel & Corporate Secretary
Comp: $646.25k
Dr. Nancy Valente M.D. (Age 65)
Executive VP & Chief Development Officer
Comp: $28.16k
Mr. Charles Liles
Associate Director and Head of Corporate Communications & Investor Relations
Ms. Jennifer Sandoz
Vice President of Human Resources
Dr. Jeremy Grunstein Ph.D.
Senior Vice President of Business Development
Mr. Kirk Rosemark RAC (Age 59)
Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. Eric P. Kowack
Senior Vice President of Program Leadership & Alliance Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XNCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Xencor stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" XNCR shares.
View XNCR analyst ratings or view top-rated stocks.
What is Xencor's stock price target for 2024?: 9 brokers have issued twelve-month target prices for Xencor's shares. Their XNCR share price targets range from $24.00 to $50.00. On average, they predict the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 88.9% from the stock's current price.
View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts.
How have XNCR shares performed in 2024?: Xencor's stock was trading at $21.23 at the start of the year. Since then, XNCR stock has decreased by 10.2% and is now trading at $19.06.
View the best growth stocks for 2024 here.
When is Xencor's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our XNCR earnings forecast.
How were Xencor's earnings last quarter?: Xencor, Inc. (NASDAQ:XNCR) issued its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of $0.36 by $0.67. The biopharmaceutical company had revenue of $44.70 million for the quarter, compared to analysts' expectations of $77.63 million. Xencor had a negative trailing twelve-month return on equity of 18.67% and a negative net margin of 74.90%. The company's revenue for the quarter was up 106.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.20) EPS.
What ETFs hold Xencor's stock?: ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Genomics Immunology and Healthcare ETF (IDNA).ALPS Medical Breakthroughs ETF (SBIO).

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?: 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.
What other stocks do shareholders of Xencor own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).
Who are Xencor's major shareholders?: Xencor's stock is owned by many different institutional and retail investors. Top institutional investors include Diversified Trust Co (0.02%), Los Angeles Capital Management LLC (0.02%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais and Kurt A Gustafson.
View institutional ownership trends.
How do I buy shares of Xencor?: Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XNCR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial